Prostatype Genomics AB (publ)

kr 0.10As of Sun 8 Nov 2026, 12:00 UTC
STO:PROGENHealthcare
Country Sweden
PE (Fwd) •••
TSR 6Y CAGR (81.85%)
Div yield —
ROE (176.16%)
Diagnostics & Research
Beta (5Y) 1.47
PE TTM —
TSR TTM (85.11%)
Mkt cap kr 68.16M
ROIC (108.81%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
kr 0.102
3.22%
10.42%
Hold 7|5|7|8|0
4Q25
1Q26
2Q26
3Q26
Earnings per sharekr
—
—
—
—
36.55%
36.72%
24.29%
19.00%
Revenuekr M
6.994
7.163
7.145
7.361
4.50%
1.20%
3.59%
4.44%
Peers (US$6.891M)
Cap (US$)
PE
16.27M
—
Capital
TTM
5Y
10Y
Leveragex
1.068
0.035
0.035
EBIT/Intx
1.116
0.259
0.210
Own earn%
(44.73)
(54.08)
(51.25)
Sh yield%
35.24
49.69
48.36
Owners
Insiders/Inst%
2.14
29.36
Short interest%
5.43
SBC / revenue%
4.25
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
6
Op margin range%
24–27
$1 testx
—
Incr. ROIC%
17